Objective: The objective of this clinical trial is to study the effectiveness of administering recombinant activated factor VII (rFVIIa) in reducing the amount of bleeding and the need for homologous blood and products transfusion in cardiac surgical coronary revascularization procedures done under cardiopulmonary bypass (CPB). Methods: In a randomized controlled prospective observational study, 30 patients were scheduled for elective cardiac revascularization under CPB. Patients were randomly allocated into two groups. In Group I (Control group), no rFVIIa was administered following CPB. In Group II (Study group), a dose of 90 ug/Kg of rFVIIa was administered following weaning off CPB. The total amount of chest tube drain during the 1 st 2...
Significant post-operative bleeding can be encountered in a small population of pediatric surgical p...
Abstract Background Recently, there has been an increased use of recombinant activated factor VII (r...
Objective: Review the use of recombinant activated Fac-tor VII following cardiac surgery. Specifical...
A retrospective observational study to review the safety and efficacy of rFVIIa in persistent hemorr...
Background: The control of excessive bleeding after paediatric cardiac surgery can be challenging. T...
The aim of this case series is to review the effect of recombinant activated factor VIIa (rFVIIa) on...
Objective: Perioperative microvascular bleeding is associated with increased morbidity and mortality...
AbstractA retrospective observational study to review the safety and efficacy of rFVIIa in persisten...
and trials of recombinant activated factor VII (rFVIIa) for bleed-ing during surgery. The reports of...
Objective: Perioperative microvascular bleeding is associated with increased morbidity and mortalit...
ObjectiveRefractory bleeding after complex cardiovascular surgery often leads to increased length of...
We reviewed the outcome following use of recombinant activated factor VII (rVIIa) in patients with m...
Objectives: Recombinant activated factor VII (rFVIIa) is used in various surgical procedures to redu...
Contexte : L'hémorragie en chirurgie cardiaque est une complication non exceptionnelle et aux conséq...
ObjectivesPost-operative haemorrhage is a recognised complication and independent predictor of outco...
Significant post-operative bleeding can be encountered in a small population of pediatric surgical p...
Abstract Background Recently, there has been an increased use of recombinant activated factor VII (r...
Objective: Review the use of recombinant activated Fac-tor VII following cardiac surgery. Specifical...
A retrospective observational study to review the safety and efficacy of rFVIIa in persistent hemorr...
Background: The control of excessive bleeding after paediatric cardiac surgery can be challenging. T...
The aim of this case series is to review the effect of recombinant activated factor VIIa (rFVIIa) on...
Objective: Perioperative microvascular bleeding is associated with increased morbidity and mortality...
AbstractA retrospective observational study to review the safety and efficacy of rFVIIa in persisten...
and trials of recombinant activated factor VII (rFVIIa) for bleed-ing during surgery. The reports of...
Objective: Perioperative microvascular bleeding is associated with increased morbidity and mortalit...
ObjectiveRefractory bleeding after complex cardiovascular surgery often leads to increased length of...
We reviewed the outcome following use of recombinant activated factor VII (rVIIa) in patients with m...
Objectives: Recombinant activated factor VII (rFVIIa) is used in various surgical procedures to redu...
Contexte : L'hémorragie en chirurgie cardiaque est une complication non exceptionnelle et aux conséq...
ObjectivesPost-operative haemorrhage is a recognised complication and independent predictor of outco...
Significant post-operative bleeding can be encountered in a small population of pediatric surgical p...
Abstract Background Recently, there has been an increased use of recombinant activated factor VII (r...
Objective: Review the use of recombinant activated Fac-tor VII following cardiac surgery. Specifical...